Corbus Pharmaceuticals (CRBP) announced data from its first-in-human dose escalation clinical study conducted in the United States and the United Kingdom of CRB-701 will be presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, to be held in San Francisco, CA February 13-15, 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP: